Regional Analysis
Basal Insulin Market Regional Insights:
- North America is expected to be the largest market for basal insulin during the forecast period, accounting for over 43.2% of the market share in 2023. The growth of the market in North America is attributed to the high diabetes prevalence, favorable reimbursement policies, and early adoption of advanced insulin delivery devices. For instance, according to Center for Disease Control and Prevention (CDC), 37.3 million people had diabetes in the U.S. in 2022, and a total of 28.7 million people were diagnosed including 28.5 million adults.
- Europe is expected to be the second-largest market for the basal insulin market, accounting for over 25.2% of the market share in 2023. The growth of the market in is attributed to the rising geriatric population and increasing awareness about diabetes management.
- Asia Pacific is expected to be the fastest-growing market for basal insulin, growing at a CAGR of over 12.1% during the forecast period. The growth of the market in Asia Pacific is attributed to the rapidly increasing diabetic population and healthcare expenditure in emerging countries.
Figure 1. Global Basal Insulin Market Share (%), by Region, 2023
| Geographies covered: |
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
|
U.S.: 
U.K. : 
India : 
